Search clinical trials for: Biocon Insulin 70/30

Total 154 results

Biocon Limited
Profil Institut für Stoffwechselforschung GmbH

Completed

Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30

Healthy Volunteer

Germany
Wockhardt

Terminated

Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics

Type I Diabetes

United States, India
Novo Nordisk A/S

Completed

Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes (UPGRADE)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Korea, Republic of
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Former Serbia and Montenegro
Novo Nordisk A/S

Completed

Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes (IMPROVE™)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, China, India, Iran, Islamic Republic of, Korea, Republic of, Russian Federation, Poland, Japan, Italy, Canada, Greece
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs (IMPROVE)

Diabetes Mellitus, Type 2 | Diabetes

Turkey
Novo Nordisk A/S

Completed

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Delivery Systems

Indonesia
Novo Nordisk A/S

Completed

Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Norway, Sweden
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®

Diabetes Mellitus, Type 2 | Diabetes

Tunisia
Novo Nordisk A/S

Completed

Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Romania
Novo Nordisk A/S

Completed

Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2 | Diabetes

Israel
Novo Nordisk A/S

Completed

Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins

Diabetes Mellitus, Type 2 | Diabetes

Hungary
Novo Nordisk A/S

Completed

Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes (IMPROVE Life)

Diabetes Mellitus, Type 2 | Diabetes

India
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Medical University of Graz

Completed

Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids (HUCKEPACK2)

Type 2 Diabetes

Austria
Novo Nordisk A/S

Completed

Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Netherlands, United Kingdom
Novo Nordisk A/S

Completed

Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Denmark
Novo Nordisk A/S

Completed

Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes (PRESENT)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of
Dennis G. Karounos, M.D.
Novo Nordisk A/S

Completed

Veterans Inpatient Insulin Study and Transition to Outpatient Therapy (VIISTA)

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs

Diabetes Mellitus, Type 2 | Diabetes

Mexico
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment (Start)

Diabetes Mellitus, Type 2 | Diabetes

Finland
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes (SimpleMix™)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, Poland, Spain, India, Argentina, China
Novo Nordisk A/S

Completed

Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes (Start)

Diabetes Mellitus, Type 2 | Diabetes

Sweden
Novo Nordisk A/S

Completed

Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland
Novo Nordisk A/S

Completed

Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes (ProMix)

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Post Marketing Surveillance Study of Biphasic Insulin Aspart 30

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Korea, Republic of
Novo Nordisk A/S

Completed

Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes (REACH)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes (EFFECTIVE)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Former Serbia and Montenegro
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands (SWITCH)

Diabetes Mellitus, Type 2 | Diabetes

Netherlands
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Jordan
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers

Healthy | Diabetes

United States
Novo Nordisk A/S

Completed

Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin (Mix2Mix)

Diabetes Mellitus, Type 2 | Diabetes

Belgium, Luxembourg
Novo Nordisk A/S

Completed

Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Canada
Novo Nordisk A/S

Completed

Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Macedonia, The Former Yugoslav Republic of
Sanofi

Terminated

Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting (BASAAL PLUS)

Diabetes Mellitus, Type 2

Netherlands
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Diabetes | Type 2 Diabetes Mellitus

Taiwan, Turkey, India, Algeria, Hong Kong, China, Ukraine
Novo Nordisk A/S

Completed

Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Slovakia
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes (SAFE)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Philippines
Novo Nordisk A/S

Completed

Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

South Africa

3

Subscribe